Search clinical trials for: Alemtuzumab (MabCampath, BAY86-5045) and Fludarabine Phosphate (Fludara, BAY86-4864)

Total 34 results

Genzyme, a Sanofi Company

Completed

Vitalis Study - Observational Study on the Quality of Life in Patients Under Treatment for B-Chronic Lymphocytic Leukemia (B-CLL)

Leukemia, B-Cell, Chronic

Italy
Genzyme, a Sanofi Company

Terminated

Safety, Effectiveness and Patient Acceptance of the Treatment With MabCampath in Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia

Macedonia, The Former Yugoslav Republic of, Bosnia and Herzegovina, Israel
Genzyme, a Sanofi Company

Completed

A Safety Confirmatory Study of Alemtuzumab in Japanese Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

Leukemia, Lymphocytic, Chronic, B-Cell

Japan
Genzyme, a Sanofi Company

Completed

Fludara (Oral) Phase II Study for Indolent Lymphoma

Lymphoma

Japan
Genzyme, a Sanofi Company

Completed

A Study to Confirm the Efficacy and Safety of Fludarabine Phosphate Administered in Untreated Chronic Lymphocytic Leukemia Patients With Anemia and/or Thrombocytopenia

Leukemia, Lymphocytic, Chronic, B-Cell
Genzyme, a Sanofi Company

Completed

Efficacy and Safety Study of Oral Fludarabine Phosphate in Combination With Mitoxantrone as First Line Treatment in Follicular NHL

Non Hodgkin Lymphoma

Italy
Genzyme, a Sanofi Company

Completed

Efficacy and Safety Study of SH T 586 in Combination With Rituximab to Treat Low-Grade NHL

Lymphoma, Low-Grade

Japan
Arbeitsgemeinschaft medikamentoese Tumortherapie
Schering-Plough

Completed

A Pilot Trial With Subcutaneous Alemtuzumab and Oral Fludarabinephosphate for the Determination of Safety, Efficacy and Molecular Profiling for the Prediction of Response

B-cell Chronic Lymphocytic Leukemia

Austria
Genzyme, a Sanofi Company

Completed

Fludarabine (Fludara®) Plus Alemtuzumab (CAMPATH®, MabCampath®) vs Fludarabine Alone in B-Cell Chronic Lymphocytic Leukemia (B-CLL) Patients

B-Cell Chronic Lymphocytic Leukemia

Sweden, United States, Croatia, Canada, Ukraine, Austria, Bulgaria, France, Germany, Greece, Italy, Poland, Portugal, Romania, Russian Federation
M.D. Anderson Cancer Center

Completed

Safety and Efficacy of Campath in Nonmyeloablative Transplantation

Lymphoma | Leukemia

United States
Masonic Cancer Center, University of Minnesota

Terminated

Reduced Intensity Hematopoietic Cell Transplantation for Patients With Resistant Langerhans Cell Histiocytosis

Histiocytosis, Langerhans-cell

United States
Hackensack Meridian Health

Completed

Stem Cell Transplantation for Sickle Cell Anemia

Sickle Cell Disease

United States
M.D. Anderson Cancer Center
Bayer

Completed

Cyclophosphamide, Fludarabine, Alemtuzumab, and Rituximab (CFAR) for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Chronic Lymphocytic Leukemia

United States
German CLL Study Group
Genzyme, a Sanofi Company; University of Cologne

Completed

Combined Immunochemotherapy in Patients With T-Prolymphocytic Leukemia (T-PLL)

T-cell-prolymphocytic Leukemia

Germany
M.D. Anderson Cancer Center
Bayer

Completed

CFAR Study in Patients With Chronic Lymphocytic Leukemia

Leukemia | Chronic Lymphocytic Leukemia

United States
Masonic Cancer Center, University of Minnesota

Recruiting

Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies

Common Variable Immunodeficiency | Chronic Granulomatous Disease | Hemophagocytic Lymphohistiocytosis | Wiskott-Aldrich Syndrome | X-linked Lymphoproliferative Disease | Langerhan's Cell Histiocytosis | Chediak-Higashi Syndrome | Griscelli Syndrome | Bare Lymphocyte Syndrome | SCID | Omenn's Syndrome | Reticular... and other conditions

United States
Steven E. Coutre
Bayer

Completed

Phase 2 Fludarabine, Cytoxan and FCCAM <Alemtuzumab> in Untreated B-Cell Chronic Lymphocytic Leukemia

Leukemia | Chronic Lymphocytic Leukemia (CLL) | Chronic Leukemia | B-cell Leukemia

United States
M.D. Anderson Cancer Center

Completed

Allo Transplantation With Mylotarg, Fludarabine and Melphalan for AML, CML and MDS

Chronic Lymphocytic Leukemia | Myelodysplastic Syndrome | Acute Myelogenous Leukemia

United States
National Cancer Institute (NCI)

Completed

Fludarabine, Rituximab, and Alemtuzumab in Treating Patients With Chronic Lymphocytic Leukemia

B-cell Chronic Lymphocytic Leukemia | Stage I Chronic Lymphocytic Leukemia | Stage II Chronic Lymphocytic Leukemia | Stage III Chronic Lymphocytic Leukemia | Stage IV Chronic Lymphocytic Leukemia

United States
Randy Windreich

Completed

Reduced-Intensity Conditioning (RIC) and Myeloablative Conditioning (MAC) for HSCT in AML/MDS

Acute Myeloid Leukemia (AML) | Myelodysplastic Syndrome (MDS) | Hematopoietic Stem Cell Transplant (HSCT)

United States
M.D. Anderson Cancer Center

Completed

Non-Myeloablative Allogeneic Stem Cell Transplantation

Lymphoma

United States
Masonic Cancer Center, University of Minnesota

Completed

Allogeneic Transplantation For Severe Osteopetrosis

Severe Osteopetrosis

United States
Masonic Cancer Center, University of Minnesota
National Marrow Donor Program

Completed

Stem Cell Transplant for Hemoglobinopathy

Sickle Cell Disease | Thalassemia | Severe Congenital Neutropenia | Diamond-Blackfan Anemia | Shwachman-Diamond Syndrome

United States
Northside Hospital, Inc.
Blood and Marrow Transplant Group of Georgia

Terminated

Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Cancer

Lymphoma | Myelodysplastic Syndromes | Leukemia | Myelodysplastic/Myeloproliferative Diseases

United States
LEO Pharma
Bayer

Completed

Efficacy and Safety Study of Advantan for Maintenance Treatment of Atopic Dermatitis

Dermatitis, Atopic
M.D. Anderson Cancer Center

Terminated

Planned Donor Lymphocyte Infusion (DLI) After Allogeneic Stem Cell Transplantation (SCT)

Lymphoma | Leukemia | Myeloma | Myeloproliferative Diseases

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI); National Heart, Lung, and Blood Institute...

Completed

Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies

Recurrent Adult Acute Myeloid Leukemia | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent... and other conditions

United States, Italy
Fred Hutchinson Cancer Center
National Cancer Institute (NCI); National Heart, Lung, and Blood Institute...

Completed

Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by a Donor Stem Cell Transplant in Treating Patients With Immunodeficiency or Other Nonmalignant Inherited Disorders

Immunodeficiency Syndrome | Non-Cancer Diagnosis

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer

Chronic Myelomonocytic Leukemia | Recurrent Adult Acute Myeloid Leukemia | Juvenile Myelomonocytic Leukemia | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell... and other conditions

United States, Italy
M.D. Anderson Cancer Center

Completed

Natural Killer (NK) Cell Adback After Allogeneic Stem Cell Transplant With Campath-IH Plus Chemorx for Patients With Lymphoid Malignancies

Lymphoma | Leukemia

United States
M.D. Anderson Cancer Center
Bayer

Terminated

Autologous and Allogenic Transplantation With Campath-1H for T-Cell Lymphoma

Lymphoma

United States
M.D. Anderson Cancer Center
Bellicum Pharmaceuticals

Terminated

Donor Lymphocyte Infusion (DLI) of T-cells Genetically Modified With iCasp9 Suicide Gene

Leukemia | Myeloma | Myeloproliferative Diseases

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Untreated Adult Acute Myeloid Leukemia | Myelodysplastic Syndrome With Excess Blasts | High Risk Myelodysplastic Syndrome | de Novo Myelodysplastic Syndrome | Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1 | Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11 | Acute Myeloid... and other conditions

United States
National Cancer Institute (NCI)

Completed

Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia | Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1

United States

Search clinical trials for: Alemtuzumab (MabCampath, BAY86-5045) and Fludarabine Phosphate (Fludara, BAY86-4864)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Jamaica

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations